Rossari Biotech Q1 FY27 Revenue & EBITDA Hit Record Highs; Transcript Released
Rossari Biotech reported record Q1 FY27 revenue of ₹697.2 crore (up 28% YoY) and EBITDA of ₹80.6 crore (up 18.7% YoY). Core B2B operations achieved ₹85 crore EBITDA with 14% margins. The company is focused on asset monetization, product mix improvement, and leveraging new capacities for sustainable growth.
Record financial performance and positive outlook on future growth, capacity utilization, and strategic expansions typically have a significant impact on investor sentiment and the company's valuation.
The company reported record revenue and EBITDA, indicating strong operational performance and growth. Strategic initiatives for margin improvement and expansion were also highlighted.
Rossari Biotech Limited announced its Q1 FY27 results, reporting its highest ever quarterly revenue and EBITDA. Consolidated revenue grew by 28% year-on-year (YoY) to ₹697.2 crore, driven by strong performance in the Home, Personal Care & Performance Chemicals (HPPC), Textile Specialty Chemicals (TSC), and Animal Health & Nutrition (AHN) segments. EBITDA also reached a record high of ₹80.6 crore, a 18.7% YoY increase, though EBITDA margins were at 11.6% compared to 12.5% in the prior year's same quarter. The company's core B2B operations showed resilience with an EBITDA of ₹85 crore and a margin of approximately 14%.
Management highlighted strategic initiatives including the monetization of non-core assets, rationalization of lower-margin businesses, and product mix improvement to enhance profitability. The company is focusing on leveraging its expanded capacities, accelerating new product development, and improving operational efficiencies. The new R&D center is operational and contributing to faster product development.
Expansion efforts include strengthening the textile specialty chemicals portfolio with a new Fibre Chemicals Division and broadening presence in agrochemicals. Internationally, a greenfield blending plant in Thailand has been established, and progress is being made on a proposed initiative in Saudi Arabia. The company's revenue growth was supported by both domestic momentum and international expansion, with exports growing 21% YoY.
The transcript of the Earnings Conference Call held on July 20, 2026, for Q1 FY27 has been released and is available on the company's website. Key management personnel present included Mr. Edward Menezes (Promoter and Executive Chairman), Mr. Sunil Chari (Promoter and Managing Director), and Mr. Ketan Sablok (Group Chief Financial Officer).
What to do with a filing like this
Rossari Biotech Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Rossari Biotech Limited. Read the original for the full detail.